Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 9/20 | 0.68 |
| ▸ | ACHE | P22303 | 8/20 | 0.68 |
| ▸ | BCHE | P06276 | 6/20 | 0.68 |
| ▸ | PDE5A | O76074 | 5/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | METAP1 | P53582 | 1/20 | 0.58 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4863010 | 0.90 | GBA1 (0.58) | APPACHEBCHEPDE5AMAPK1 | |
| SCHEMBL4857481 | 0.87 | LMNA (0.64) | APPACHEBCHEPDE5AMAPK1 | |
| SCHEMBL4866244 | 0.87 | MAPK1 (0.59) | APPACHEBCHEMAPK1LMNA | |
| SCHEMBL4859938 | 0.84 | RAD52 (0.69) | APPACHEBCHEPDE5AMAPK1 | |
| SCHEMBL4859337 | 0.81 | ACHE (0.50) | APPACHEBCHEPDE5AMAPK1 | |
| SCHEMBL4856835 | 0.80 | APP (0.69) | APPACHEBCHEPDE5AMAPK1 | |
| SCHEMBL17799869 | 0.80 | APP (1.00) | APPACHEBCHEPDE5AMAPK1 | |
| SCHEMBL1085431 | 0.79 | PDE5A (1.00) | APPPDE5AMAPK1KDM4EJAK2 | |
| SCHEMBL4894183 | 0.77 | RAD52 (0.51) | APPACHEBCHEPDE5ALMNA | |
| SCHEMBL4890406 | 0.77 | APP (0.64) | APPACHEBCHEPDE5AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | claimed |
| JP-2008526734-A | — | — | 2008-07-24 | — | — | JP | claimed |
| EP-1844023-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2007-10-17 | — | — | EP | claimed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | disclosed |
| EP-1844023-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | GPR119, GCKR, GLP1R | APP 4386/4885ACHE 371/4885BCHE 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.